| **Neuroblastoma**  
<table>
<thead>
<tr>
<th><strong>Histopathology Reporting Guide</strong></th>
</tr>
</thead>
</table>
| **Family/Last name**  
| **Date of birth** DD – MM – YYYY  
| **Given name(s)**  
| **Date of request** DD – MM – YYYY  
| **Patient identifiers**  
| **Accession/Laboratory number** DD – MM – YYYY  

Elements in **black text** are CORE. Elements in **grey text** are NON-CORE.  
☐ indicates multi-select values  
☐ indicates single select values

**SCOPE OF THIS DATASET**

Use of this dataset is only permitted subject to the details described at:  
Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org)

Version 1.0 Published November 2023  
Page 1 of 3

### Degree of Differentiation
(Applicable to neuroblastoma or nodules of ganglioneuroblastoma, nodular, that have not had chemo/radiotherapy)

- Undifferentiated
- Poorly differentiated
- Differentiating
- Cannot be determined, specify

### Mitotic-Karyorrhectic Index (MKI)
(Applicable to neuroblastoma and ganglioneuroblastoma, nodular tumour tissue that have not had chemo/radiotherapy)

- Low (<100 per 5,000 cells; <2%)
- Intermediate (100-200 per 5,000 cells; 2-4%)
- High (>200 per 5,000 cells; >4%)
- Cannot be determined, specify

### Prognostic Classification
(Based on the International Neuroblastoma Pathology Committee classification)
(Not applicable for tumours post chemo/radiotherapy)

- Favourable
- Favourable, based on review of limited material
- Unfavourable
- Cannot be determined, specify

### Treatment Effect

- Not identified
- Present

### Lymph Node Status

- Cannot be assessed
- No nodes submitted or found

<table>
<thead>
<tr>
<th>Number of lymph nodes examined</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not involved</td>
</tr>
<tr>
<td>Involved</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Number of involved lymph nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number cannot be determined</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Location of involved lymph nodes, specify</th>
</tr>
</thead>
</table>

### Ancillary Studies

- Not performed
- Performed

#### MYCN status

- Not applicable
- Cannot be determined
- Pending
- Not amplified
- Amplified
- Gain

#### DNA content

- Not performed
- DNA ploidy
  - Record method
    - Results pending
    - DNA index 1.0 (diploid)
    - DNA index >1.0 (hyperdiploid)
    - DNA index, specify value

#### CNV

- Not performed
- CNV
  - Record method
    - Results pending
    - DNA ploidy

### Immunohistochemistry, specify antibodies and results

### Other (e.g., ALK), record test(s), methodology and results

### Representative blocks for ancillary studies, specify those blocks best representing tumour and/or normal tissue for further study

---

Use of this dataset is only permitted subject to the details described at: [Disclaimer - International Collaboration on Cancer Reporting (iccr-cancer.org)](https://iccr-cancer.org)

Version 1.0 Published November 2023


Neuroblastoma

**ADDITIONAL MATERIAL FOR BIOLOGICAL/GENETIC ANALYSIS**

**Material available**
- No
- Yes
  - Not histological assessed
  - Histologically assessed

**Viable tumour present**
- No
- Yes
  - Viable tumour present
  - Neuroblastic cells
  - Schwann cells
  - Other cells (e.g., lymphoid cells, fibroblasts)

**HISTOLOGICALLY CONFIRMED DISTANT METASTASIS**
- Not applicable
- Not identified
- Present (select all that apply)
  - Liver
  - Skin
  - Bone marrow

Percentage of haemopoietic bone marrow replaced by tumour
- Cannot be determined
- ≤5%
- >5%, specify %

Bone, specify site(s)

Soft tissue, specify site(s)

Other, specify site(s)